We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$22.6B
$19M 0.2%
1,500,000
+500,000
+50% +$6.57M
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$19M 0.2%
4,350,808
– –
HALO icon
28
Halozyme
HALO
$9.88B
$18.3M 0.19%
1,931,057
– –
TGTX icon
29
TG Therapeutics
TGTX
$8.15B
$17.1M 0.18%
2,003,991
– –
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16.9M 0.18%
609,166
– –
XNPT
31
DELISTED
XENOPORT, INC.
XNPT
$15.7M 0.17%
3,475,672
– –
MDVN
32
DELISTED
MEDIVATION, INC.
MDVN
$15.2M 0.16%
329,876
-329,876
-50% -$12M
BLUE
33
DELISTED
bluebird bio
BLUE
$15M 0.16%
27,247
+16,354
+150% +$10M
FOMX
34
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.6M 0.15%
2,241,702
+194,735
+10% +$1.26M
ACGN
35
DELISTED
Aceragen Inc
ACGN
$13.8M 0.15%
51,450
+52
+0.1% +$13.9K
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$12.7M 0.13%
4,310,666
– –
LKFT
37
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$12.7M 0.13%
303,394
-65,882
-18% -$3.06M
AGIO icon
38
Agios Pharmaceuticals
AGIO
$2.09B
$12.5M 0.13%
307,915
+207,915
+208% +$8.89M
NVAX icon
39
Novavax
NVAX
$1.19B
$12.3M 0.13%
118,963
+9,179
+8% +$985K
XNCR icon
40
Xencor
XNCR
$1.44B
$11.7M 0.12%
872,072
– –
DSCI
41
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11.6M 0.12%
3,752,390
– –
OMER icon
42
Omeros
OMER
$834M
$11.5M 0.12%
749,250
+413,024
+123% +$5.02M
EXEL icon
43
Exelixis
EXEL
$14.1B
$10.3M 0.11%
+2,580,000
New +$10.9M
DMTX
44
DELISTED
Dimension Therapeutics, Inc
DMTX
$9.8M 0.1%
1,251,881
+17,400
+1% +$137K
GBT
45
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.52M 0.1%
600,000
+200,000
+50% +$3.55M
ASND icon
46
Ascendis Pharma A/S
ASND
$16.7B
$9.38M 0.1%
505,521
– –
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$9.24M 0.1%
1,000,000
– –
ARCT icon
48
Arcturus Therapeutics
ARCT
$161M
$8.86M 0.09%
333,766
– –
ALKS icon
49
Alkermes
ALKS
$8.12B
$8.56M 0.09%
250,251
– –
ATYR
50
aTyr Pharma
ATYR
$47.2M
$8.42M 0.09%
152,686
-14,109
-8% -$1.07M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Baker Bros. Advisors held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Baker Bros. Advisors withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Baker Bros. Advisors's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Baker Bros. Advisors added most to Incyte in Q1 2016, an estimated $300M increase.
  • Baker Bros. Advisors's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Baker Bros. Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Baker Bros. Advisors's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q1 2016.
  • Baker Bros. Advisors's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.